Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBK1 | Q9UHD2 | 11/20 | 0.51 |
| ▸ | NSD2 | O96028 | 1/20 | 0.41 |
| ▸ | FYN | P06241 | 1/20 | 0.40 |
| ▸ | JAK2 | O60674 | 4/20 | 0.39 |
| ▸ | SRC | P12931 | 4/20 | 0.39 |
| ▸ | GAK | O14976 | 3/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | JAK1 | P23458 | 1/20 | 0.39 |
| ▸ | TYK2 | P29597 | 1/20 | 0.39 |
| ▸ | JAK3 | P52333 | 1/20 | 0.39 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.38 |
| ▸ | COQ8A | Q8NI60 | 2/20 | 0.38 |
| ▸ | NLK | Q9UBE8 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4582113 | 0.87 | TBK1 (0.42) | TBK1SRCGAKEGFRRIPK2 | |
| SCHEMBL4581125 | 0.87 | SRC (0.41) | TBK1SRCGAKEGFRRIPK2 | |
| SCHEMBL4581296 | 0.82 | TBK1 (0.42) | TBK1NSD2FYN | |
| SCHEMBL4578991 | 0.81 | SRC (0.40) | TBK1SRC | |
| SCHEMBL4579223 | 0.79 | MAPK10 (0.47) | TBK1FYNJAK2SRCGAK | |
| SCHEMBL4580156 | 0.76 | AR (0.44) | TBK1NSD2FYN | |
| SCHEMBL4581082 | 0.76 | PRKCQ (0.40) | TBK1NSD2JAK2JAK1JAK3 | |
| SCHEMBL4581106 | 0.76 | AR (0.39) | TBK1NSD2FYN | |
| SCHEMBL4581544 | 0.71 | PRKCQ (0.42) | TBK1FYNEGFR | |
| SCHEMBL4581874 | 0.71 | SRC (0.42) | SRCGAKEGFRRIPK2COQ8A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080076800-A1 | Benzene, Pyridine, and Pyridazine Derivatives | SERENEX, INC. | 2008-03-27 | — | — | US | claimed |
| US-20080076800-A1 | Benzene, Pyridine, and Pyridazine Derivatives | SERENEX, INC. | 2008-03-27 | — | — | US | disclosed |
| US-20080076800-A1 | Benzene, Pyridine, and Pyridazine Derivatives | SERENEX, INC. | 2008-03-27 | — | — | US | disclosed |
| US-20080076800-A1 | Benzene, Pyridine, and Pyridazine Derivatives | SERENEX, INC. | 2008-03-27 | — | — | US | disclosed |
| WO-2008024963-A1 | BENZENE, PYRIDINE, AND PYRIDAZINE DERIVATIVES | SERENEX, INC. (US) | 2008-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076800-A1 | Benzene, Pyridine, and Pyridazine Derivatives | RB1, MKI67, CCNB1 | TBK1 2196/4885NSD2 2177/4885FYN 584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.